Introduction
During early embryogenesis, the seemingly equivalent and likely multipotent pancreatic precursors give rise to both exocrine (acinar and ductal) or endocrine islet cells, in generally reproducible proportions (Gu et al., 2002; Kawaguchi et al., 2002; Seymour et al., 2007; Zhou et al., 2007) . Neurog3 (Neurogenin3 or Ngn3) is essential for endocrine differentiation. All endocrine islet cells are derived from pancreatic progenitors that transiently express high levels of Neurog3 (Gu et al., 2002; Mellitzer et al., 2004; Schonhoff et al., 2004) . Loss of Neurog3 activity nearly abolishes endocrine islet cell differentiation (Gradwohl et al., 2000; Wang et al., 2008) . Conversely, ectopic expression of Neurog3 results in precocious endocrine differentiation from embryonic endodermal cells, with a differential stage-dependent output of islet cell types (Apelqvist et al., 1999; Grapin-Botton et al., 2001; Schwitzgebel et al., 2000) . Remarkably, co-expression of Neurog3 with MafA and Pdx1 converts adult acinar cells into β-like islet cells (Zhou et al., 2008) . Thus, understanding Neurog3 expression and function is essential for elucidating islet cell neogenesis, and may be relevant for both in vitro differentiation of ES cells and in vivo exocrine cell transdifferentiation, towards endocrine islets [ (Yang and Wright, 2009; Zaret, 2009) 
and references therein].
Previous studies have suggested that Neurog3 + cells are selected by Notch-mediated lateral inhibition from a set of multipotent pancreatic progenitor cells (MPCs) that maintain active Notch signaling (Apelqvist et al., 1999; Jensen et al., 2000b) . Specifically, activated Notch converts transcriptional repressor RBP-J{kappa}/ CBF1 to an activator to up-regulate the expression of Hes (orthologs of Hairy enhancer of split) or Hairy-related (Hey) genes (Fujikura et al., 2006) . Protein products of the Hes and Hey gene family members directly repress Neurog3 transcription (Jensen et al., 2000b) to allow for MPC maintenance. Stochastic events or asymmetries developed during cell division cause a subset of MPCs to reduce the strength of Notch signaling and raise Neurog3 level above a specific threshold level for islet cell specification and commitment (Apelqvist et al., 1999; Jensen et al., 2000b) . Neurog3 directly activates the expression of several transcription factor genes (Mellitzer et al., 2006; Petri et al., 2006; White et al., 2008) . Subsequently, these transcription factors cooperatively activate the expression of endocrine hormones and other necessary genes that are involved in islet cell development and maturation (Artner et al., 2007; Huang et al., 2000; Wang et al., 2007) . During the Developmental Biology 339 (2010) [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] differentiation process, short-lived intermediate cell types that only express these transcription factors but not hormones have been detected and are proposed to be different-staged endocrine progenitors (Artner et al., 2007; Chiang and Melton, 2003; Jensen et al., 2000a) . Whether the level of Neurog3 expression or the activation of any specific Neurog3 targets is the limiting step for producing mature and functional islet cells remains unclear.
Other than activating the endocrine differentiation program, Neurog3 was proposed to mediate lateral inhibition to properly allocate the specific proportions of pancreatic MPCs to endocrine and exocrine fates in a non-cell autonomous fashion (Skipper and Lewis, 2000) . By analogy to studies of neuronal development (Kageyama et al., 2008) , it was proposed that Neurog3 upregulates the expression of Notch ligand(s), raising nuclear Notch signaling in adjacent cells non-cell-autonomously and preventing them from activating Neurog3 expression (Lewis, 1998; Meinhardt and Gierer, 1974) . A result of lateral inhibition is the preservation of mitotically active pancreatic MPCs, which is critical for generating adequate endocrine mass because most Neurog3 expressing cells are mitotically quiescent and differentiated islet cells have limited proliferation capability (Gu et al., 2002; Jensen et al., 2000a; Stanger et al., 2007) . This model predicts that the level of Neurog3 expression in individual pancreatic progenitor cells is critical for controlling the proportion of progenitors that activate Neurog3 expression.
Here, we demonstrate that a low level of Neurog3 expression in individual pancreatic cells is not sufficient to cause full differentiation and end-stage endocrine hormone production. Consequently, a portion of the Neurog3-expressing cells, possibly those expressing low levels of Neurog3, adopts exocrine (both acinar and ductal) cell fates. This finding suggests that pancreatic progenitor cells that turn on a low level of Neurog3 maintain a substantial degree of plasticity to revert to exocrine progenitors: we propose that they are therefore endocrine-biased and metastable. We further show that lowering Neurog3 production activates Neurog3 in a larger proportion of pancreatic progenitor cells, although the transcription levels of Notch ligands in cells that express different levels of Neurog3 are not significantly altered. This latter finding suggests that Neurog3 mediates lateral inhibition with a Notch ligand transcriptionindependent pathway(s) to control the abundance of Neurog3 + cells.
Materials and methods

Mouse strains and care
Mouse strain derivation/maintenance, crosses and treatments follow protocols approved by the Vanderbilt Medical Center IACUC. The noon of vaginal plug appearance was counted as embryonic day 0.5 (E0.5). Routine mouse embryo production utilized CD1 mice (Charles River Laboratories, Inc. Wilmington, MA). The Neurog3 F and Neurog3 − mouse strains were described previously (Wang et al., 2008) . Neurog3
TgBAC-Cre ; R26R EYFP and Neurog3 EGFP knockin mice were generous gifts from A. Leiter (Schonhoff et al., 2004) , F. Costantini (Srinivas et al., 2001) , and K. Kaestner (Lee et al., 2002) , respectively. Genotyping follows published methods with minor modification. Briefly, tissue from an ear puncture was collected, boiled in 40 mM NaOH for 30 min. An equal volume of 0.1 mM Tris (pH: 5.0) was added to neutralize. 1-3 μl of lysate was used in PCR genotyping.
Immunodetection
Immunofluorescence (IF) and immunohistochemistry followed established protocols. Tissues were prepared either as frozen or paraffin sections. For frozen sections, dissected tissues were immediately frozen in OCT and sectioned on the day of staining. Guinea pig anti-glucagon, guinea pig anti-insulin, guinea pig anti-PP, and rabbit anti-SS were from Dako, Carpinteria, CA. Rat anti-BrdU (BU1/75), goat anti-amylase, and rabbit anti-Ki67 were from ABCam, Cambridge, MA. Mouse anti-mouse alpha tubulin and Dolichos Biflorus Agglutinin (DBA) were from Sigma Aldrich, St Louis, MI. Secondary antibodies used were: Cy3-conjugated donkey anti-rabbit IgG, Cy3-conjugated donkey anti-mouse IgG, FITC-conjugated donkey anti-guinea pig IgG, Cy3-conjugated donkey anti-goat, Cy5-conjugated donkey antiguinea pig IgG; and Cy5-conjugated donkey anti-rabbit (Jackson Immunoresearch, West Grove, PA). All antibodies utilized 1:500-1:2000 dilutions, depending on the amount of tissue on each slide.
Assays and quantification
Intraperitoneal glucose tolerance test (IPGTT), serum insulin assays, and insulin secretion from isolated islets were performed as described (Wang et al., 2007) . Western blot utilized α-tubulin as loading control. 20 or 10 μg of total protein was loaded for each lane. In order to assay islet mass, pancreata of each stage were weighted, fixed, and prepared as 6 μm paraffin sections. One of every 10 sections was collected and stained with a mix of antibodies against insulin, glucagon, PP, and SS, respectively, as HRP signals. Slides were counterstained with hematoxylin. Sections were then scanned by Ariol SL-50 (Genetix, Hampshire, UK) for quantitative IHC analysis to calculate the ratio of the stained endocrine area over that of the total pancreas. The islet mass was calculated based on the endocrine/exocrine ratio and pancreas weight.
In order to examine the mitotic index of different pancreatic cells, animals were injected IP with multiple doses of BrdU (at 50 mg/kg body weight). For P1 animals, two doses at 2-h interval were injected. For P10 animals, 4 doses at 2-h interval were injected. Pancreata were then collected 2 h after the last BrdU injection. Pancreata were then prepared as paraffin sections to assay for BrdU + cells, which were visualized by IF and confocal imaging. Multiple images/sections from each pancreas were counted to obtain representative labeling indices.
Microscopy
Confocal microscopy (Zeiss LSM500) was utilized to visualize fluorescent images. Samples were processed side by side. Images were captured using identical confocal parameters as Z-sections of one μm thickness. Images were then projected onto a single plane for side-byside comparison for protein level/cell quantification.
Fluorescence activated cell sorting and real time RT-PCR (QRTPCR)
E14.5 pancreata were dissected and genotyped. Batches of 8-10 individual EGFP + pancreata were dissociated into single cells using a mix of trypsin (0.05%) and Type IV collagenase (1 mg/ml). EGFP + cells were collected using FACS. Before further analysis, a portion of collected cells were spun onto glass slides utilizing Cytospin (Thermo Shandon, Oak Park, MI) and examined for purity (by analyzing the expression of hormones, and the presence of EGFP). The rest of the samples were utilized for RT-PCR, with two duplicate cDNA preparations and four QRT-PCR (quantitative RT-PCR) reactions to assay the mRNA levels. For each genotype, a minimum of three independent batches of embryos was processed independently (i.e. the mRNA level for each gene will be an average of 12 assays). Reverse-transcription PCR (RT-PCR) follows standard protocol. cDNA synthesis and RT-PCR were done by using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). QRT-PCR was performed using mouse-specific primers ( mice displayed significantly compromised glucose-clearance capability at all ages tested, including 1 and 2 months after birth (Fig. 1A) . The Neurog3 F/− mice showed a trend of lower glucose clearing capability at 1 month of age than Neurog3 +/− animals. This trend became undetectable after 2 months of age (Fig. 1A) . Despite being glucose intolerant, the Neurog3 +/− and Neurog3 F/− animals do not develop frank diabetes (ad lib-feeding blood glucose over 300 mg/dl) even at 1 year of age (not shown). In order to investigate whether the glucose-clearing defect in Neurog3 +/− and Neurog3 F/− animals is due to either compromised insulin secretion from β cells or reduced response of peripheral tissues to insulin, we examined insulin sensitivity. Overnight fasted adult mice were administered with insulin by intraperitoneal injection. Their blood glucose level was assayed at different time points after the insulin injection. All three groups of animals, when examined at 2 months of age, displayed similar profiles of blood glucose reduction in response to insulin administration (Fig. 1B) , demonstrating an unaltered insulin sensitivity. Consistent with this insulin tolerance result and the IPGTT defects above, the fasting serum insulin levels did not vary significantly between these three genotypes ( Fig. 1C ). Yet 30 min after glucose challenge, the Neurog3 +/− and Neurog3 Neurog3 production is reduced in Neurog3 +/− and Neurog3
We then determined the underlying mechanisms for the compromised endocrine function in Neurog3 +/− and Neurog3 F/− animals.
We first examined Neurog3 production in pancreata at several embryonic stages, E13.5, E15.5, and E16.5, using semi-quantitative immunofluorescence (IF), western blot, and real time RT-PCR. For IFstaining-based assays, pancreata of different genotypes were dissected and processed identically, side-by-side. After IF-staining, confocal image series (as Z-sections of 1 micron thickness) were captured under identical parameters and stacked as single images, so that the fluorescence of multiple nuclear focal planes was integrated to estimate the total fluorescence intensity within individual nuclei (Materials and methods). The average Neurog3 levels in each progenitor cell were visibly reduced in Neurog3 +/− and Neurog3 F/− pancreata ( Supplementary Fig. 1 ), as were the number of cells that express high levels of Neurog3, with the caveat that this type of nuclear abundance estimation is semi-quantitative ( Fig. 2A ) , and Neurog3 F/− pancreata (E15.5) (Fig. 2C) . The lowered Neurog3 F mRNA level could be a result of its destabilization by the presence of a long 3′-UTR (Amrani et al., 2006) .
Reduced Neurog3 dosage decreases endocrine islet mass
We also investigated how the level of Neurog3 produced affects endocrine function. In the adult pancreas, overall islet architecture did not vary among the various genotypes, with β cells mostly localized within the islet core and α, δ, and PP cells localized peripherally (data not shown). Significantly, the average islet size and the abundance of sectioned islets appeared reproducibly reduced in the order of WT, Neurog3 +/− , and Neurog3 F/− (Fig. 3A-C) . We estimated the total islet mass by measuring islet area in several animals of various genotypes in a subset of pancreatic sections (see Materials and methods). Total islet mass was substantially reduced at P1 (postnatal day 1) and P28 in Neurog3 +/− and Neurog3 F/− animals than in Neurog3 +/+ animals ( Fig. 3D) . In order to examine whether a reduction of Neurog3 expression affects endocrine function of each islet cell after differentiation, we examined the expression of several factors that are critical for endocrine function after birth. We found that the hormone expressing islet cells in all three groups of animals expressed similar levels of Pdx1, Nkx6.1, Glut2, MafA, and MafB on per cell basis ( Supplementary Fig. 2 ). This finding suggests that the Neurog3 level per cell does not appreciably affect endocrine differentiation, provided that the Neurog3 level is high enough to allow endocrine commitment (and differentiation) to be completed. In addition, we tested the insulin secretion capability of islets isolated from 6-weekold pancreata from the three groups of animals. To our surprise, the straightforward Neurog3 +/− heterozygous islets displayed a trend, although statistically insignificant, of increased insulin secretion over that of wild-type islets, in response to glucose stimulation. In accordance with this trend, Neurog3 F/− islets showed significantly animals. It could represent an unknown aspect of improper differentiation. Alternatively, it could represent an adaptive behavior of the islets, which up-regulate glucose-induced insulin secretion to compensate for insulin insufficiency. Such a process is known to occur prior to phenotypic manifestation of Type II Diabetes in human patients (Prentki and Nolan, 2006) .
The Neurog3 expression level does not affect pancreatic cell proliferation
In order to examine whether a reduced Neurog3 production compromises pancreatic cell proliferation, we assayed pancreatic weight and cell division at various stages. At P1, P10, and P16, the pancreatic mass normalized to body weight remains unchanged in wild type, Neurog3 +/− , and Neurog3 F/− animals ( Supplementary   Fig. 3 ). We assayed both the mitotic indices with BrdU incorporation in the exocrine (ducts, acini) and the four major endocrine cell types (α, β, δ, and PP). At E17.5 and P10, two representative stages when pancreatic cells are actively dividing, the mitotic indices of these specific pancreatic cells in wild type, Neurog3
, and Neurog3 F/− pancreata were similar (Fig. 4 and Supplementary Fig. 4 ). These combined data suggest that Neurog3 dosage does not affect cell division and that the observed endocrine mass reduction in Neurog3 +/− and Neurog3 F/− animals are likely caused by reduced neogenesis (i.e. direct differentiation of Neurog3 + progenitors to form islet endocrine cells) during embryogenesis, rather than compromised cell proliferation during fetal or postnatal animal growth. Along this line, we examined whether the fate or number of Neurog3 + cells was altered when Neurog3 dosage was reduced.
Lowered Neurog3 dosage shunts Neurog3 + cells to an exocrine cell fate
Neurog3
CreERT transgene or knock-in mouse-based lineage studies with the Z/AP reporter line (Lobe et al., 1999) have shown that most, if not all, pancreatic progenitors that express a high level of Neurog3 will adopt an endocrine islet cell fate (Gu et al., 2002; Johansson et al., 2007) . Neurog3 TGBAC-Cre transgenic-BAC-based studies suggest that a low but significant fraction of pancreatic progenitors that express Neurog3, detected with the more sensitive Cre reporter R26R, gives rise to exocrine cells (Schonhoff et al., 2004; CW, unpublished observations) . Based on these latter findings, we hypothesized that the level of Neurog3 is critical for moving pancreatic progenitors to an endocrine-biased condition. We tested to see if lowering Neurog3 expression level in individual cells would allow more Neurog3 + cells to divert to an exocrine fate. This possibility could explain why endocrine islet cell production is reduced in Neurog3 +/− and Neurog F/− animals. -labeled cells were found to express exocrine cell markers in the wild-type background, about 45% of the labeled cells were found within the exocrine lineage in the heterozygous Neurog3 +/− pancreas: more Neurog3 + precursors adopt an exocrine fate with Neurog3 dosage reduction (Fig. 5D ).
These data strongly suggest that Neurog3 expression must reach a threshold ("high") level in order to trigger the commitment of progeny towards endocrine differentiation. At lower Neurog3 levels, many more progeny of Neurog3-expressing cells maintain multipotent-progenitor-like activity and can "reallocate" to the exocrine acini or duct fates. Consistent with this hypothesis, total inactivation of Neurog3 did not eliminate the presence of cells that activated the Neurog3 promoter. Instead, the cells that activated the Neurog3 promoter (and therefore also induced to express Cre from Neurog3 TgBAC-Cre ) were relocated to the exocrine tissues, including exocrine acinar and pancreatic ducts (Fig. 5C ). We also examined the fate of Neurog3 + cells in the Neurog3 F/− compound heterozygous animals (hypomorphic floxed allele over null) using the Neurog3 
Lowered Neurog3 dosage results in wider Neurog3 expression in pancreatic progenitors
We counted the total number of pancreatic cells derived from in Neurog3 +/− animals, the faster division of exocrine cells could lead to more EYFP + descendents. This possibility is known to play a role for the increased EYFP + pancreatic cells in Neurog3 +/− mice because acinar cells divide twice as frequently as endocrine islet cells (Fig. 4  and supplementary Fig. 4) (Fig. 6C) . 
Reducing Neurog3 activity does not reduce Notch ligand expression at a global level
Overall, the findings above demonstrate that the Neurog3 protein level within specific cells can feed back to the epithelium to regulate the production of Neurog3 + cells, which is consistent with the hypothesis that Neurog3 expression is linked to a lateral inhibition process (Skipper and Lewis, 2000) . In the classical Notch-based lateral inhibition model, down-regulation of nuclear Notch activity lowers the Hes/Hey expression that is responsible for activating the cellautonomous proneural gene expression (which is the pro-endocrine gene Neurog3 in endocrine pancreatic development). One function of the proneural gene is to raise the expression of Notch ligands, Delta or Jagged, which consequently potentiate Notch activity in neighboring progenitors, and repress expression of proneural genes in these neighbors. Because our above finding is consistent with Neurog3 normally being intimately linked to lateral inhibition, such that its expression is prevented from spreading to neighboring cells, we tested for evidence of which Notch ligand was utilized. We again utilized the knockin mouse line, Neurog3 (Fig. 7) . The expression of Hes6, although detected at high levels in EGFP + cells, did not vary between Neurog3 EGFP/+ and Neurog3 EGFP/F pancreata (Fig. 7) . Consistent with a recent report that
Mfng expression depends on Neurog3 activity (Golson et al., 2009; Svensson et al., 2009) We also assayed the expression of several pancreatic progenitor markers, including Ptf1a (Kawaguchi et al., 2002) , Mist1 (Pin et al., 2001) , and Sox9 (Seymour et al., 2007 
Discussion
Endocrine islet cells have a limited capacity to divide under normal physiological conditions, and this process may be restricted further by isotype-specific proliferation [e.g., beta cells only producing beta cells (Herrera, 2000; Dor et al., 2004) ]. Therefore, islet mass in individual animals is predominantly determined by the controlled allocation of pancreatic progenitors to the endocrine lineage during organogenesis (Stanger et al., 2007) . While it is known that activation of Neurog3 in pancreatic progenitors is essential for cells to adopt the endocrine fate, it remains unclear how only a specific portion of pancreatic progenitors activates Neurog3 expression, or how the Neurog3 level within each cell affects endocrine differentiation. Here, we show that the high level of Neurog3 expression within individual progenitor cells is critical for the allocation of pancreatic progenitor cells towards the endocrine cell lineage. We further show that although reduced Neurog3 expression causes more pancreatic progenitors to activate low levels of Neurog3 expression (Neurog3 LO) , most of these Neurog3 LO cells are incapable of becoming endocrine cells, and many move to exocrine fates. Thus, a reduction in Neurog3 dosage results in a net reduction of endocrine differentiation.
High Neurog3 activity drives endocrine commitment
Examination of Neurog3 expression at various stages of pancreas organogenesis detects cells with low (Neurog3 LO ) or high (Neurog3 HI ) levels of Neurog3 (Apelqvist et al., 1999; Gradwohl et al., 2000; Gu et al., 2002; Schwitzgebel et al., 2000; Villasenor et al., 2008) 
Conversely, Neurog3
TgBAC-Cre -based lineage tracing showed that, even in the wild-type situation, a portion of Neurog3-expressing precursors gives rise to exocrine cells (Schonhoff et al., 2004) . These combined findings lead to the hypothesis that the Neurog3 LO progenitor cells maintain some degree of plasticity towards exocrine fates. Our findings here demonstrate that, indeed, Neurog3 activity must reach a high level for endocrine differentiation to occur. Most Neurog3 LO cells, if they fail to activate high Neurog3 expression, adopt exocrine (acinar or ductal) cell fates. Therefore, pancreatic progenitors maintain their multipotency, i.e. the ability of a group of cells to give rise to multiple cell types, until their respective Neurog3 expression reaches a specific level. In other words, pancreatic progenitors are not pre-selected to become endocrine progenitors before Neurog3 activation. This Neurog3 level "check point" provides pancreatic MPCs with some tolerance to the fluctuation of endocrine-inducing signals: if low levels of Neurog3 were to be induced in most pancreatic progenitors either due to stochastic events, gene expression fluctuation, or even in the presence of certain gene mutations, progenitors would not be forced to differentiate into endocrine islet cells. This mechanism would provide a way to prevent premature pancreatic MPCs exhaustion because of improper endocrine differentiation.
Why a low level of Neurog3 expression is not sufficient to activate the endocrine differentiation program, or repress exocrine differentiation, is not clear. It is likely that the various Neurog3 target genes possess different Neurog3 recognition sequences or combinations of different motifs with different affinities to Neurog3. As a result, high levels of Neurog3 are required to activate a set of targets, which are all necessary for endocrine differentiation. At low levels, Neurog3 might activate only some of its targets, a situation insufficient to commit and move from the progenitor state. Our recent finding of Neurog3 function in differentiated β cells is consistent with this type of speculation (Wang et al., 2009) . In that study, we found that differentiated islet cells maintain a low yet detectable level of Neurog3 expression. We further showed that a selective deletion of Neurog3 in newly born or mature adult β cells compromised the expression of several, but not all, known Neurog3 targets (Wang et al., 2009 cells. Yet the reduction in the number of Neurog3 HI cells leads to more pancreatic epithelial cells to activate Neurog3 expression. As a result, these "extra" Neurog3 + (most likely expressing a 'medium level' of Neurog3) will partially compensate for the loss of some progenitors that would have normally expressed the highest levels of Neurog3 to adopt endocrine islet cell fate (Fig. 8B) . Surprisingly, a lowered Neurog3 activity does not significantly reduce the transcription levels of any Notch ligand that has been tested, a finding seemed to contradict the hypothesis that Neurog3 normally up-regulates Notch ligand expression to mediate the classical lateral inhibition (Skipper and Lewis, 2000) . It is possible that the real time RT-PCR assays are not sensitive enough to detect a small reduction in the transcription of individual Notch ligands (e. g., Delta1 in Fig. 7) . Alternatively, Neurog3 could utilize post-transcriptional mechanism to regulate Notch activity. For example, Neurog3 could regulate the sub-cellular localization of Notch ligands. It is also possible Neurog3 could modulate Notch activity through modifiers such as Mfng (whose expression is reduced when Neurog3 expression level is reduced), as demonstrated by biochemical analysis (Panin et al., 2002) . Lastly, it is also possible that the classical lateral inhibition does not apply in the Notch-Ngn3 pathway. Instead, the altered endocrine differentiation could in turn affect Neurog3 expression indirectly through non-Notch ligands (eg., some unknown soluble molecules) or non-Notch receptor dependent pathways. It would be of interest in the future to explore these latter possibilities.
In summary, our analysis revealed a previously unrecognized impact of Neurog3 level on endocrine production. These findings underscore the importance of understanding Neurog3 expression control, including its expression pattern and its expression level in individual cells, for both endocrine differentiation and diabetes development for future studies.
